origin and ITH was illustrated at the transcriptomic, genotypic, cell-cycle state, molecular 73 pathways, and phenotypic levels. Finally, the cell-of-origin-based analysis of PC tumor cells led 74 to a 12-gene fundamental signature, which although derived from PC cells, retained its 75 prognostic significance when applied to several independent localized and advanced large-scale 76 GAC cohorts. These results provide an avenue for patient stratification and novel target 77 discovery for future therapeutic exploitation. 78 79 A single-cell transcriptome map of PC 80 scRNA-seq was performed on freshly isolated ascites cells from 20 GAC patients ( Fig. 1a , 81 Table S1 ). Following quality filtering, we acquired high-quality data for 45,048 cells. A 82 multistep approach was applied to identify PC malignant cells and define immune cell types (see 83 Methods). We captured 6 main cell types: tumor cells, fibroblasts, and 4 immune cell types, 84 each defined by unique signature genes (Extended Data Fig. 1) . The immune cells from 85 different patients clustered by cell type, whereas PC malignant cells clustered distinctly by 86 patient. But it was evident that tumor cells from the short-term survivors clustered closely in t-87 SNE plot (t-distributed stochastic neighbor embedding, Extended Data Fig. 2) . In this study, we 88 have focused on PC tumor cells (n=31,131). Five patients with too few tumor cells (<50) were 89 excluded from subsequent analysis. To profile the transcriptomic landscape of PC tumor cells, 90 unsupervised cell clustering was carried out, which uncovered 14 unique cell clusters, with 91 differentially expressed genes (DEGs) specifically marking each cell cluster (Fig. 1b, Extended  92 Data Fig. 3) . It is worth mentioning that tumor cells from patient IP-070 formed two separated 93 clusters (2 and 12). These results indicated a high degree of inter-and intra-tumoral 94 heterogeneities in PC malignant cells. 95 96 5
The cell-of-origin of malignant cells within the peritoneal cavity 97
To map each individual PC tumor cell and to determine its cell of origin (genotype/phenotype), 98
we performed cell-of-origin analysis by mapping scRNA-seq data to Human Cell Landscape 99 (http://bis.zju.edu.cn/HCL/), a scRNA-seq database that comprises >630k cells covering 1,393 100 cell types/states from 44 human organs/tissues (see Methods). Our analysis revealed a high 101 degree of cellular heterogeneity in PC (the diversity of origins of tumor cells that comprised the 102 tumor). Intriguingly, although all cases in this study were clinically diagnosed as PC from GAC, 103 our transcriptome-based cell-of-origin analysis revealed 14 defined cell types originated from 7 104 organs ( Fig. 1c , Table S2 ). Only 60% of mapped PC tumor cells transcriptomically resembled 105 cells of stomach origin, including pit cells (41%), mucosal cells (19%), and chief cells (0.4%). 106 However, the expression features of a subset of PC tumor cells (23%) closely resembled cells of 107 other GI (gastrointestinal) organs, including colon (15%), pancreas (3%), rectum (2%), 108 duodenum (1%), and gallbladder (1%). For case IP-070, our analysis suggested that no PC tumor 109 cells were of GI origin, instead, the cells transcriptomically resembled breast luminal epithelial 110 cells (Extended Data Fig. 4) . After a comprehensive review of the patient's clinical record, we 111 noted that this case was misdiagnosed and treated as GAC at an outside hospital but it was breast 112 cancer that metastasized to the stomach resulting in PC subsequently. This vignette reflected the 113 accuracy of our cell-of-origin analysis. 114
115
The diversity in tumor cell origins is a key determinant of PC transcriptomic ITH with 116 prognostic value 117
To further study ITH and examine its relationship with tumor cell origins, we performed 118 unsupervised clustering of PC tumor cells separately for each individual case based on 119 transcriptomic profiles and then projected the cell-of-origin annotation on generated tSNE plots. 120
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The representative results are shown in Fig. 1d . We observed a separation (different 121 transcriptomic profiles) of the cells showing a gastric lineage from the cells demonstrating a 122 colonic lineage (IP-067, IP-158, IP-010) in tSNE plots. Notably, the stomach pit cells also 123 clustered distinctly from stomach mucosal cells (IP-009). DEGs analysis revealed gene 124 expression signatures specific to each cell population ( Fig. 1e) . Our results demonstrated that PC 125 tumor cells with different cell origins are transcriptomically distinct and suggested that the 126 diversity in tumor cell origins is likely a determinant of ITH. For two cases (IP-158 and IP-010) 127 with mixed stomach/colon cell lineages, we were able to retrieve the histology images of the 128 corresponding GAC primary tumors and confirmed tumors arose in the setting of gastric 129 intestinal metaplasia, characterized by the presence of well-formed goblet cells in gastric mucosa 130 ( Fig. 1f) . This finding is intriguing given the associated analysis showing a mixed cellular 131 population of both gastric and colorectal lineages. 132
Based on the cellular compositions, we classified PC into two main groups: the Gastric-133 dominant (dominated by gastric cell lineages) and the GI-mixed (with mixed gastric and 134 colorectal cell lineages) ( Fig. 1c) . We further investigated the correlation of cell-of-origin-based 135 classification with clinical/ histopathological variables, and no significant difference was 136 observed for histopathological features between two groups. Notably, the cell-of-origin based 137 classification of PC tumor cells showed a strong correlation with patient survival (Fig. 1g) To study the ITH of tumor cell proliferative property and examine its link to tumor cell-of-origin, 145
we computationally assigned a cell cycle stage to each individual cell based on expression profile 146 of cell-cycle related signature genes 11 (see Methods). Our analysis suggested that 51% of PC 147 tumor cells are cycling, either in G2M or S phase ( Fig. 2a, Table S3 ). Interestingly, tumor cell 148 proliferative property strongly correlated with tumor cell origins (Fig. 2b) . The stomach pit cells 149 were highly proliferative, with vast majority of cells in G2M/S phase, while the stomach mucosal 150 cells and cells of colorectal origins were quiescent. Consistently, some key cell-cycle regulatory 151 genes were differentially expressed across tumor cell populations with different origins and 152 associated with patient survival (Fig. 2c) . 153 154
The Genotypic ITH of PC tumor cells links to cell-of-origin 155
We next investigated the genotypic ITH of PC tumor cells and examined its association with 156 tumor cell origins. Single-cell copy number variations (CNVs) were inferred from scRNA-seq 157 data 10,12,13 (see Methods). The inferred CNVs showed considerable patient-to-patient and cell-to-158 cell variations ( Fig. 3) , indicating a significant genotypic heterogeneity among PC tumor cells. 159
For each individual patient, we further investigated copy number subclonal structures of PC 160 tumor cells using unsupervised hierarchical clustering. Intriguingly, the pattern of CNV 161 subclonal structures aligned well with tumor cell origins (Fig. 3a) . For example, for case IP-067, 162 PC tumor cells clustered into 3 major subpopulations with distinct CNV profiles: the largest 163 subpopulation was mainly comprised of cells of colon lineage and distinguished by number of 164
CNVs from the smallest subpopulation that was purely comprised of cells of stomach lineage, a 165 subpopulation in medium size was a mixture of cells from both lineages and the cells shared 166 similar CNV profiles. Similarly, 3 populations were identified in IP-009 that was gastric-167 8 dominant (Fig. 3a, bottom) , and the smallest subpopulation (comprised of stomach pit cells) 168 showed additional CNVs that were not present in the subpopulation that was mainly comprised 169 of stomach mucosal cells. 170
In addition, we analyzed CNVs from all cases together and discovered 17q amplification as a 171 unique event that was highly abundant in tumors cells with stomach origin and only present in 172 cells from short survivors (Fig. 3b) . By integrating genotypic and transcriptomic profiles, we 173 identified a list of upregulated genes on 17q in tumor cells with evident 17q amplification 174 (compared to the rest of cells without amplified 17q) ( Fig. 3c , Table S4 ). Some of these 175 upregulated genes involved in key signaling pathways (PI3K/AKT/mTOR, mTORC1, MYC), 176 are potential therapeutic targets (NOTCH1, GRB2, PSMB3) with a number of compounds being 177 screened as active 14 (Table S5) , and associated with patient survival (Fig. 3d) . Our results 178 demonstrated that the genotypic ITH in PC tumor cells associated with tumor cell origin and 179 patient survival. 180 181
Single-cell molecular signaling heterogeneity correlated with tumor cell-of-origin 182
To examine the molecular consequences of transcriptomic and genotypic alterations described 183 above and to better understand the biological programs associated with cell-of-origin and patient 184 survival, we performed integrative analysis of >900 molecular signaling pathways. Among them, 185 80 pathways were differentially expressed across tumor cell origins (Fig. 4a) , and of these, 37 186
were also strongly associated with patient survival (Fig. 4b, Extended Data Fig. 6 ). These 187 pathways were categorized into 5 major classes based on their biological functions: oncogenic 188 signaling, cell cycle, DNA repair, metabolism, and immune signaling ( Fig. 4c) . Pathway 189 interactions analysis revealed that these biological processes are functionally connected. 190 Pathways that were significantly enriched in tumor cells with gastric lineage and associated 191 with shorter survival included cell cycle, DNA repair, PI3K/AKT/mTOR, mTORC1, Wnt, NFκB, 192 and metabolic reprogramming, which are predominantly oncogenically encoded. In contrast, 193 pathways that were enriched in tumor cells with colon lineage and associated with longer 194 survival included defensins, IL-7 signaling, complement cascade, IL6/JAK/ STAT3 signaling, 195 and interferon alpha/gamma, which are exclusively immune related ( Figs. 4a-b) . These results 196 indicated that different biological processes might have been activated in tumor cells with 197 different origins and contributed to their distinct molecular consequences and patient survival. 198 199
Generation and validation of a cell-of-origin based 12-gene prognostic signature 200
Based on cell-of-origin analysis, a 12-gene signature was derived ( Figs. 5a-b, Methods) . We 201 first validated this signature in an independent, advanced GAC cohort (n=45) using bulk seq data. This signature demonstrated a great power to prognosticate patient survival and 203 consistently, patients with a Gastric-dominant molecular feature in their PC cells survived 204 significantly shorter (7.8 vs. 24.5 month) than those with a GI-mixed feature (Fig. 5c) . 205
Multivariable Cox regression analysis showed that this signature is a strong prognosticator of 206 short survival and it outperformed all clinical variables and was independent of 207 clinical/histopathological features (Extended Data Fig. 7) . 208
We next evaluated its prognostic significance in 5 other large-scale localized GAC 209 cohorts 13,15-17 , totaling 1,425 patients. Notably, although this signature was derived from an 210 advanced GAC cohort, it retained its prognostic prowess in these validation cohorts of localized 211
GACs and demonstrated a robust power in prognosticating survival (Fig. 5c) . Intriguingly, this 212 signature is independent of other molecular and clinical subtypes (Extended Data Fig. 8 ) and it 213 10 correlated strongly with the risk of local recurrence/distal metastases among the TCGA 8 and 214
Cristescu cohorts 17 , where expression and outcome data are both available ( Fig. 5d , Extended 215 Data Fig. 9 ). These results further highlighted the value of this prognostic signature and its 216 robustness in prognosticating patient survival. 217
218 Discussion 219
The progress against GAC has lagged behind other GI tumor types. Therapy resistance and the 220 lack of rational therapeutic targets against GAC represent major obstacles in improving survival 221 of advanced GAC patients 18 . It is widely appreciated that ITH is a fundamental property of 222 cancer contributing to therapeutic failure, development of distant metastases, 19 and hindrance to 223 biomarker/target discoveries 20 . Recent studies of localized and advanced GACs identified 224 multiple molecular subtypes and revealed a high degree of ITH that are associated with poor 225 clinical outcomes 9,21,22 . Therefore, deeper dissection of ITH is critical for understanding the 226 underlying mechanisms driving poor prognosis of GAC and for overcoming therapeutic 227 resistance. In this study, we dissected, at unprecedented resolution, the cellular and 228 transcriptomic ITH of PC tumor cells using the cutting-edge scRNA-seq technology, in 229 combination with integrative computational analyses. 230
A key finding of this study is that diversity of cell-of-origin appears to mirror and may even 231 dictate inherent ITH of PC tumor cells at multiple molecular levels. The origin of ITH has been 232 the subject of discussion, with multiple models being proposed 23, 24 . Peritoneal cavity is a unique 233 microenvironment where tumor cells can be in suspension in the peritoneal fluid as opposed to 234 localized solid tumor tissues, the ascites cells we have sequenced may be a better representation 235 of ITH. We discovered several transcriptomically distinct tumor cell populations that could be 236 distinguished by cell lineage characteristics. We noted that >40% of cases in our discovery 237 11 cohort had a large number of tumor cells with genotype/phenotype mapping to non-stomach GI 238 lineages. We documented that ITH defined by cell-of-origin is perpetuated at transcriptomic, 239 genotypic, cell-cycle state, molecular signaling, and phenotypic levels and strongly associated 240 with survival. We showed that tumor cell transcriptomic profiles and proliferative property 241 significantly differed across cells with different origins, so did the molecular signaling, 242
suggesting that treatment strategies could potentially be tailored to these molecular features. It 243 would appear that varied biological programs (e.g. genomic/epigenomic) might have been 244 engaged early in tumor cells resulting in different genotypes/phenotypes and subsequently 245 contributed to distinct molecular ITH and patient prognosis. In addition, we discovered that 17q 246 amplification was highly abundant in PC cells of gastric lineage. 17q is a region that harbors 247 multiple potential therapeutic targets and interestingly, all patients with 17q amplification had a 248 short survival. Our discovery of the direct link between tumor cell-of-origin and ITH at the 249 single-cell resolution could be generalized to other cancer types and broaden our understanding 250 of cancer in general. 251
Most intriguingly, the cell-of-origin-based analysis classified PC tumor cells into two cellular 252 subtypes that were prognostic independent of histopathological features. Further analyses led us 253 to discover a 12-gene signature that appears to be fundamental to GAC 254 carcinogenesis/propagation as it was not only highly prognostic in GAC metastatic validation 255 cohort but perform just as robustly in several large-scale localized GAC cohorts. Currently, there 256 is no such signature in clinical use and this signature has a high potential to stratify patients for 257 more effective therapies as this becomes available. 258
259

METHODS
12
A total of 20 GAC patients with malignant ascites (peritoneal carcinomatosis, PC) was included 262 in this study. The detailed clinical and histopathological characteristics are described in the 263 Supplementary Table S1 . GACs were staged according to the American Joint Committee on 264 Cancer Staging Manual (8th edition) 25, 26 . PC was confirmed by cytologic examination. This 265 cohort included 10 long-term survivors and 10 short-term survivors. The long-term survivors 266 were patients who survived more than 1 year after the diagnosis of PC and the short-term 267 survivors were patients who passed away within 6 months after the diagnosis of PC. Genomics. Detailed QC metrics were generated and evaluated. Genes detected in <3 cells and 304 cells where < 200 genes had nonzero counts were filtered out and excluded from subsequent 305 analysis. Low quality cells where >15% of the read counts derived from the mitochondrial 306 genome were also discarded. After applying these QC criteria, 45,048 single cells and 23,057 307 genes in total remained and were included in subsequent downstream analysis. Possible batch 308 effects were evaluated using principal component analysis (PCA). In this study, all sequencing 309 14 libraries were constructed using the same version of reagent kits following the same protocols 310 and the libraries were sequenced on the same illumine platform. Therefore, no significant batch 311 effects were observed. Library size normalization was performed in Seurat 27 on the filtered gene-312 cell matrix to obtain the normalized UMI count as previously described 28 . 313 314 Unsupervised cell clustering and dimensionality reduction: Seurat 27 was applied to the 315 normalized gene-cell matrix to identify highly variable genes for unsupervised cell clustering. To 316 identify highly variable genes, the MeanVarPlot method in the Seurat 27 package was used to 317 establish the mean-variance relationship of the normalized counts of each gene across cells. We 318 then chose genes whose log-mean was between 0.0125 and 3 and whose dispersion was above 319 0.5, resulting in 3,018 highly variable genes. The elbow plot was generated with the 320
PCElbowPlot function of Seurat 27 and based on which, the number of significant principal 321 components (PCs) were determined. Different resolution parameters for unsupervised clustering 322 were then examined in order to determine the optimal number of clusters. For this study, the first 323 10 PCs and the highly variable genes identified by Seurat 27 were used for unsupervised 324 clustering with a resolution set to 0.6, yielding a total of 20 cell clusters. The t-distributed 325 stochastic neighbor embedding (t-SNE) method was used for dimensionality reduction and 2-D 326 visualization of the single cell clusters. 327 328
Determination of major cell types and cell states:
To define the major cell type of each single 329 cell that mapped to the tSNE plot, feature plots were firstly generated for a suggested set of 330 canonical immune and stromal cell marker genes 29, 30 . Enrichment of these markers in certain 331 clusters was considered a strong indication of the clusters representing the corresponding cell 332 types. In addition, differentially expressed genes (DEGs) were identified for each cell cluster 333 using the FindAllMarkers analysis in the Seurat 27 package, followed by a manual review process. 334
The two approaches are combined to infer major cell types for each cell cluster according to the 335 enrichment of marker genes and top-ranked differentially expressed genes in each cell cluster, as 336 previously described 30 In addition to the scRNA-seq dataset generated internally for this GAC PC cohort, we included 373 the bulk mRNA-seq data generated on an independent GAC PC cohort from our recent study 9 to 374 validate the 12-gene prognostic signature. Moreover, we downloaded the bulk mRNA-seq 375 expression data (normalized) generated by The Cancer Genome Atlas (TCGA) on primary 376 stomach adenocarcinoma from NCI Cancer Genomic Data Commons (NCI-GDC: 377 https://gdc.cancer.gov). The mRNA-seq expression data was processed and normalized by the 378 NCI-GDC bioinformatics team using their transcriptome analysis pipeline and we downloaded 379 the normalized expression data. The clinical annotation of TCGA patients were downloaded 380 from a recent PanCanAtlas study 32 . Furthermore, we downloaded 5 large-scale primary GAC 381 datasets (GSE14208, GSE62254, GSE15459, GSE84437) from the Gene Expression Omnibus 382 (GEO) database (GEO, https://www.ncbi.nlm.nih.gov/geo/) to further evaluate the prognostic 383 power of our identified 12-gene signature. 384 385
Generation and validation of the 12-gene prognostic signature 386
To generate a gene expression signature that is clinically applicable, we performed multiple-step 387 analysis (Fig. 5a) . First, we compared the gene expression profiles of the cell-of-origin based 388 classification of two patient groups (gastric-dominant vs. GI-mixed) and identified differentially 389 expressed genes (DEGs) between the two groups. Only the DEGs that are highly expressed 390 (normalized UMI count >1) in at least 50% of cells from one of the two groups were taken into 391 subsequent analysis. We next screened each DEG based on their statistical correlation with 392 patient survival and only the DEGs showed a significant (P<0.05) (or a clear trend, P<0.15) 393 correlation with patient survival were selected, followed by model testing of all possible multiple 394 gene combinations. The signature was then extracted and subject to validation with both 395 internally generated and publicly available datasets. To select the optimal classification threshold 396 for tumor classification, use the signature score, we tested different possible signature score 397 values and the threshold value 0 was selected. Tumors with a signature score value >0 were 398 classified as gastric-dominant, and tumors with a signature score value <0 were classified as GI-399 mixed. Higher signature scores correlate with the gastric-dominant phenotype and with worse 400 prognosis. For the bulk expression datasets, the signature scores were calculated using the 401 18 normalized gene expression values, taking into consideration of the direction of association (a 402 positive score is assigned for genes associated with the gastric-dominant subtype and a negative 403 score is assigned for genes associated with the GI-mixed subtype). The signature scores were 404 further normalized for subsequent survival analysis. 405 406
Statistical analysis 407
In addition to the bioinformatics approaches described above for scRNA-seq data analysis, all 408 other statistical analysis was performed using statistical software R v3.5.2. Analysis of 409 differences on a continuous variable (such as gene expression, pathway score) across two groups 410 (a categorical independent variable, such as gastric-dominant vs. GI-mixed) was determined by 411 the nonparametric Mann-Whitney U test. The nonparametric Kruskal-Wallis test was applied to 412 assess the significant difference on a continuous variable by a categorical independent variable 413 with multiple groups (such as the different tumor cell of origin groups). Survival analysis: For 414 survival analysis including overall survival (OS), Progression-free interval (PFS), disease-free 415 survival (DFS), disease-specific survival (DSS), disease-free interval (DFI), and survival time 416 from peritoneal metastasis, we used the log-rank test to calculate p-values, between groups, and 417 the Kaplan-Meier method to plot survival curves. For the TCGA dataset, the clinical annotation 418 and the times calculated for OS, DFS, DSS, DFI were downloaded from the PanCanAtlas study 32 . 419 For other large-scale primary GAC datasets downloaded from GEO, the relevant clinical data 420 and OS times were downloaded from their published studies 13,15-17 . The hazard ratios were 421 calculated using the multivariate Cox proportional hazards model. All statistical significance 422 testing in this study was two-sided. To control for multiple hypothesis testing, we applied the 423 Benjamini-Hochberg method to correct p values and the false discovery rates (q-values) were 424 calculated. Results were considered statistically significant at p-value or FDR q-value < 0.05. 425 426
Data availability 427
All sequencing data generated during this study will be deposited in the Gene Expression 428
Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/). The data can be accessed under the 429 accession number GSExxxxxx (the submission process is currently ongoing, and the accession 430 number is going to be updated once it is complete). 431 432
